{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:47:14Z","timestamp":1793386034661,"version":"4.5.0"},"reference-count":71,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100013093","name":"Shenzhen Science and Technology Planning Project","doi-asserted-by":"publisher","award":["JCYJ20190812161605538"],"award-info":[{"award-number":["JCYJ20190812161605538"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Key Laboratory","award":["ZDSYS20210623092000002"],"award-info":[{"award-number":["ZDSYS20210623092000002"]}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission Project","doi-asserted-by":"publisher","award":["JCYJ202205 31092014034"],"award-info":[{"award-number":["JCYJ202205 31092014034"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Traditional Chinese Medicine Hospital \u2018\u20183030 Program\u2019\u2019 Chinese Medicine Clinical Project","award":["G3030202115"],"award-info":[{"award-number":["G3030202115"]}]},{"name":"Guangdong Provincial Enterprise Joint Project","award":["2022A1515220189"],"award-info":[{"award-number":["2022A1515220189"]}]},{"DOI":"10.13039\/501100006469","name":"Science and Technology Development Fund, Macau SAR","doi-asserted-by":"publisher","award":["0098\/2021\/A2"],"award-info":[{"award-number":["0098\/2021\/A2"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Science and Technology Development Fund, Macau SAR","doi-asserted-by":"publisher","award":["0099\/2018\/A3"],"award-info":[{"award-number":["0099\/2018\/A3"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Non-Alcoholic Fatty Liver Disease (NAFLD) has become a significant\nhealth and economic burden globally. Yinchenhao decoction (YCHD) is a traditional Chinese\nmedicine formula that has been validated to exert therapeutic effects on NAFLD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The current study aimed to explore the pharmacological mechanisms of YCHD on\nNAFLD and further identify the potential active compounds acting on the main targets.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Compounds in YCHD were screened and collected from TCMSP and published studies,\nand their corresponding targets were obtained from the Swisstargetprediction and SEA databases.\nNAFLD-related targets were searched in the GeneCards and DisGeNet databases. The\n\u201ccompound-intersection target\u201d network was constructed to recognize the key compounds.\nMoreover, a PPI network was constructed to identify potential targets. GO and KEGG analyses\nwere performed to enrich the functional information of the intersection targets. Then, molecular\ndocking was used to identify the most promising compounds and targets. Finally, molecular\ndynamics (MD) simulations were performed to verify the binding affinity of the most potential\ncompounds with the key targets.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 53 compounds and 556 corresponding drug targets were collected. Moreover,\n2684 NAFLD-related targets were obtained, and 201 intersection targets were identified.\nBiological processes, including the apoptotic process, inflammatory response, xenobiotic metabolic\nprocess, and regulation of MAP kinase activity, were closely related to the treatment of\nNAFLD. Metabolic pathways, non-alcoholic fatty liver disease, the MAPK signaling pathway,\nand the PI3K-Akt signaling pathway were found to be the key pathways. Molecular docking\nshowed that quercetin and isorhamnetin were the potential active compounds, while AKT1,\nIL1B, and PPARG were the most promising targets. MD simulations further verified that the\nbinding of PPARG-isorhamnetin (-35.96 \u00b1 1.64 kcal\/mol) and AKT1-quercetin (-31.47 \u00b1 1.49\nkcal\/mol) was due to their lowest binding free energy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study demonstrated that YCHD exerts therapeutic effects for the treatment of\nNAFLD through multiple targets and pathways, providing a theoretical basis for further pharmacological\nresearch on the potential mechanisms of YCHD in NAFLD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115734099305489240702075128","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T05:15:31Z","timestamp":1720761331000},"page":"721-737","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Network Pharmacology and Molecular Docking Integrated with Molecular Dynamics Simulations Investigate the Pharmacological Mechanism of Yinchenhao Decoction in the Treatment of Non-alcoholic Fatty Liver Disease"],"prefix":"10.2174","volume":"21","author":[{"given":"Rong","family":"Yang","sequence":"first","affiliation":[{"name":"Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China"},{"name":"Department of Liver Diseases, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dansheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Puning Traditional Chinese Medicine Hospital, Puning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Feng","sequence":"additional","affiliation":[{"name":"Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China"},{"name":"Department of Liver Diseases, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Xing","sequence":"additional","affiliation":[{"name":"Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China"},{"name":"Department of Liver Diseases, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms21165888","volume":"2020","author":"Lonardo A.","year":"2020","unstructured":"Lonardo A.; Leoni S.; Alswat K.A.; Fouad Y.; History of nonalcoholic fatty liver disease. Int J Mol Sci  2020,2020,21","journal-title":"Int J Mol Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"Eslam M.","year":"2020","unstructured":"Eslam M.; Newsome P.N.; Sarin S.K.; Anstee Q.M.; Targher G.; Romero-Gomez M.; Zelber-Sagi S.; Wai-Sun Wong V.; Dufour J.F.; Schattenberg J.M.; Kawaguchi T.; Arrese M.; Valenti L.; Shiha G.; Tiribelli C.; Yki-J\u00e4rvinen H.; Fan J.G.; Gr\u00f8nb\u00e6k H.; Yilmaz Y.; Cortez-Pinto H.; Oliveira C.P.; Bedossa P.; Adams L.A.; Zheng M.H.; Fouad Y.; Chan W.K.; Mendez-Sanchez N.; Ahn S.H.; Castera L.; Bugianesi E.; Ratziu V.; George J.; A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol  2020,73,202-209","journal-title":"J Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"Eslam M.","year":"2020","unstructured":"Eslam M.; Sanyal A.J.; George J.; MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology  2020,158,1999-2014","journal-title":"Gastroenterology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2036.2009.04200.x","volume":"31","author":"Cabrera R.","year":"2010","unstructured":"Cabrera R.; Nelson D.R.; Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther  2010,31,461-476","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"Chen W.","year":"2016","unstructured":"Chen W.; Zheng R.; Baade P.D.; Zhang S.; Zeng H.; Bray F.; Jemal A.; Yu X.Q.; He J.; Cancer statistics in China, 2015. CA Cancer J Clin  2016,66,115-132","journal-title":"CA Cancer J Clin"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"Kulik L.","year":"2019","unstructured":"Kulik L.; El-Serag H.B.; Epidemiology and management of hepatocellular carcinoma. Gastroenterology  2019,156,477-491.e471","journal-title":"Gastroenterology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"Loomba R.","year":"2021","unstructured":"Loomba R.; Friedman S.L.; Shulman G.I.; Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell  2021,184,2537-2564","journal-title":"Cell"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2741\/4892","volume":"26","author":"Raza S.","year":"2021","unstructured":"Raza S.; Rajak S.; Upadhyay A.; Tewari A.; Anthony Sinha R.; Current treatment paradigms and emerging therapies for NAFLD\/NASH. Front Biosci  2021,26,206-237","journal-title":"Front Biosci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","volume":"49","author":"Cobbina E.","year":"2017","unstructured":"Cobbina E.; Akhlaghi F.; Non-alcoholic fatty liver disease (NAFLD) pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev  2017,49,197-211","journal-title":"Drug Metab Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","volume":"18","author":"Abdelmalek M.F.","year":"2021","unstructured":"Abdelmalek M.F.; Nonalcoholic fatty liver disease: Another leap forward. Nat Rev Gastroenterol Hepatol  2021,18,85-86","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"Targher G.","year":"2021","unstructured":"Targher G.; Corey K.E.; Byrne C.D.; Roden M.; The complex link between NAFLD and type 2 diabetes mellitus mechanisms and treatments. Nat Rev Gastroenterol Hepatol  2021,18,599-612","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105849","volume":"172","author":"Chen M.","year":"2021","unstructured":"Chen M.; Xie Y.; Gong S.; Wang Y.; Yu H.; Zhou T.; Huang F.; Guo X.; Zhang H.; Huang R.; Han Z.; Xing Y.; Liu Q.; Tong G.; Zhou H.; Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res  2021,172","journal-title":"Pharmacol Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"Friedman S.L.","year":"2018","unstructured":"Friedman S.L.; Neuschwander-Tetri B.A.; Rinella M.; Sanyal A.J.; Mechanisms of NAFLD development and therapeutic strategies. Nat Med  2018,24,908-922","journal-title":"Nat Med"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173976","volume":"898","author":"Zhou H.","year":"2021","unstructured":"Zhou H.; Ma C.; Wang C.; Gong L.; Zhang Y.; Li Y.; Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. Eur J Pharmacol  2021,898","journal-title":"Eur J Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.etp.2012.12.002","volume":"65","author":"Han J.M.","year":"2013","unstructured":"Han J.M.; Kim H.G.; Choi M.K.; Lee J.S.; Lee J.S.; Wang J.H.; Park H.J.; Son S.W.; Hwang S.Y.; Son C.G.; Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats. Exp. toxicol. pathol. offic. j. Gesellsch Toxikolog Patholog  2013,65,837-844","journal-title":"Gesellsch Toxikolog Patholog"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"15367","DOI":"10.1038\/s41598-018-33669-4","volume":"8","author":"Cai F.F.","year":"2018","unstructured":"Cai F.F.; Wu R.; Song Y.N.; Xiong A.Z.; Chen X.L.; Yang M.D.; Yang L.; Hu Y.; Sun M.Y.; Su S.B.; Yinchenhao decoction alleviates liver fibrosis by regulating bile acid metabolism and TGF-\u03b2\/Smad\/ERK signalling pathway. Sci Rep  2018,8,15367","journal-title":"Sci Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0254-6272(11)60045-9","volume":"31","author":"Chen S.D.","year":"2011","unstructured":"Chen S.D.; Fan Y.; Xu W.J.; Effects of yinchenhao decoction (see text) for non-alcoholic steatohepatitis in rats and study of the mechanism. J Tradit Chin Med  2011,31,220-223","journal-title":"J Tradit Chin Med"},{"key":"ref=18","author":"Meng Y.","year":"2018","unstructured":"Meng Y.; Meng K.; Zhao X.; Li D.; Gao Q.; Wu S.; Cui Y.; Protective effects of yinchenhao decoction on cholesterol gallstone\nin mice fed a lithogenic diet by regulating LXR, CYP7A1,\nCYP7B1, and HMGCR Pathways. Evid.based. compl. altern. med., 2018, 8134918 2018"},{"key":"ref=19","author":"Guo Y.","year":"2017","unstructured":"Guo Y.; Li J.X.; Wang Y.L.; Mao T.Y.; Chen C.; Xie T.H.; Han Y.F.; Tan X.; Han H.X.; Yinchen linggui zhugan decoction\nameliorates nonalcoholic fatty liver disease in rats by regulating the\nNrf2\/ARE signaling pathway. Evid.based. compl. altern. med., 2017, 6178358 2017"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"Schwabe R.F.","year":"2020","unstructured":"Schwabe R.F.; Tabas I.; Pajvani U.B.; Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology  2020,158(7),1913-1928","journal-title":"Gastroenterology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.3390\/cells9122572","volume":"9","author":"Kim U.","year":"2020","unstructured":"Kim U.; Kim N.; Shin H.Y.; Modeling non-alcoholic fatty liver disease (NAFLD) using \u201cgood-fit\u201d genome-editing tools. Cells  2020,9(12),2572","journal-title":"Cells"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drudis.2021.09.007","volume":"27","author":"Crampon K.","year":"2022","unstructured":"Crampon K.; Giorkallos A.; Deldossi M.; Baud S.; Steffenel L.A.; Machine-learning methods for ligand-protein molecular docking. Drug Discov Today  2022,27,151-164","journal-title":"Drug Discov Today"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8639-2_1","volume":"1825","author":"Al Mahmud R.","year":"2018","unstructured":"Al Mahmud R.; Najnin R.A.; Polash A.H.; A survey of web-based chemogenomic data resources. Methods Mol Biol  2018,1825,3-62","journal-title":"Methods Mol Biol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-1-4939-9869-2_17","volume":"2073","author":"Collier T.A.","year":"2020","unstructured":"Collier T.A.; Piggot T.J.; Allison J.R.; Molecular dynamics simulation of proteins. Methods Mol Biol  2020,2073,311-327","journal-title":"Methods Mol Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1021\/acs.jcim.0c00381","volume":"60","author":"Herrera-Nieto P.","year":"2020","unstructured":"Herrera-Nieto P.; P\u00e9rez A.; De Fabritiis G.; Small molecule modulation of intrinsically disordered proteins using molecular dynamics simulations. J Chem Inf Model  2020,60,5003-5010","journal-title":"J Chem Inf Model"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nsb0902-646","volume":"9","author":"Karplus M.","year":"2002","unstructured":"Karplus M.; McCammon J.A.; Molecular dynamics simulations of biomolecules. Nat Struct Biol  2002,9,646-652","journal-title":"Nat Struct Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13020-020-00422-x","volume":"16","author":"Liang Z.","year":"2021","unstructured":"Liang Z.; Chen X.; Shi J.; Hu H.; Xue Y.; Ung C.O.L.; Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: A systematic literature review of randomized controlled trials. Chin Med  2021,16,9","journal-title":"Chin Med"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2020.107358","volume":"90","author":"Li W.H.","year":"2021","unstructured":"Li W.H.; Han J.R.; Ren P.P.; Xie Y.; Jiang D.Y.; Exploration of the mechanism of Zisheng Shenqi decoction against gout arthritis using network pharmacology. Comput Biol Chem  2021,90","journal-title":"Comput Biol Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fphar.2020.00345","volume":"11","author":"Wu W.","year":"2020","unstructured":"Wu W.; Yang S.; Liu P.; Yin L.; Gong Q.; Zhu W.; Systems pharmacology-based strategy to investigate pharmacological mechanisms of radix puerariae for treatment of hypertension. Front Pharmacol  2020,11,345","journal-title":"Front Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13040-020-00212-z","volume":"13","author":"You J.S.","year":"2020","unstructured":"You J.S.; Li C.Y.; Chen W.; Wu X.L.; Huang L.J.; Li R.K.; Gao F.; Zhang M.Y.; Liu H.L.; Qu W.L.; A network pharmacology-based study on Alzheimer disease prevention and treatment of Qiong Yu Gao. BioData Min  2020,13,2","journal-title":"BioData Min"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1021\/acs.jcim.2c01643","volume":"63","author":"Yang R.","year":"2023","unstructured":"Yang R.; Liu L.; Jiang D.; Liu L.; Yang H.; Xu H.; Qin M.; Wang P.; Gu J.; Xing Y.; Identification of potential TMPRSS2 inhibitors for COVID-19 treatment in chinese medicine by computational approaches and surface plasmon resonance technology. J Chem Inf Model  2023,63,3005-3017","journal-title":"J Chem Inf Model"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27361","volume":"10","author":"Afzal M.","year":"2024","unstructured":"Afzal M.; Qais F.A.; Abduh N.A.Y.; Christy M.; Ayub R.; Alarifi A.; Identification of bioactive compounds of Zanthoxylum armatum as potential inhibitor of pyruvate kinase M2 (PKM2): Computational and virtual screening approaches. Heliyon  2024,10","journal-title":"Heliyon"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jpba.2007.11.014","volume":"46","author":"Wang X.","year":"2008","unstructured":"Wang X.; Sun W.; Sun H.; Lv H.; Wu Z.; Wang P.; Liu L.; Cao H.; Analysis of the constituents in the rat plasma after oral administration of Yin Chen Hao Tang by UPLC\/Q-TOF-MS\/MS. J Pharm Biomed Anal  2008,46,477-490","journal-title":"J Pharm Biomed Anal"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1002\/jssc.201600284","volume":"39","author":"Yi Y.","year":"2016","unstructured":"Yi Y.; Zhang Y.; Ding Y.; Lu L.; Zhang T.; Zhao Y.; Xu X.; Zhang Y.; Simultaneous quantitation of 14 active components in Yinchenhao decoction by using ultra high performance liquid chromatography with diode array detection: Method development and ingredient analysis of different commonly prepared samples. J Sep Sci  2016,39,4147-4157","journal-title":"J Sep Sci"},{"key":"ref=35","first-page":"257909","volume":"2013","author":"Zhang A.","year":"2013","unstructured":"Zhang A.; Sun H.; Qiu S.; Wang X.;  Advancing drug discovery and development from active constituents of yinchenhao tang, a famous traditional chinese medicine formula Evidbased complaltern medi  2013,2013,257909","journal-title":"Advancing drug discovery and development from active constituents of yinchenhao tang, a famous traditional chinese medicine formula Evidbased complaltern medi"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"11431","DOI":"10.1016\/j.biopha.2023.114311","volume":"160","author":"Zhao X.","year":"2023","unstructured":"Zhao X.; Amevor F.K.; Cui Z.; Wan Y.; Xue X.; Peng C.; Li Y.;  Steatosis in metabolic diseases: A focus on lipolysis and lipophagy Biomed pharmacoth  2023,160,11431","journal-title":"Steatosis in metabolic diseases: A focus on lipolysis and lipophagy Biomed pharmacoth"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"Younossi Z.M.","year":"2023","unstructured":"Younossi Z.M.; Golabi P.; Paik J.M.; Henry A.; Van Dongen C.; Henry L.; The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology  2023,77(4),1335-1347","journal-title":"Hepatology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/apt.17158","volume":"56","author":"Henry L.","year":"2022","unstructured":"Henry L.; Paik J.; Younossi Z.M.; Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther  2022,56,942-956","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2302\/kjm.33.127","volume":"33","author":"Kubota J.","year":"1984","unstructured":"Kubota J.; Fujino T.; Sugimoto C.; Abe T.; Long term complications caused by injected silicone gel and paraffin oil. Keio J Med  1984,33,127-136","journal-title":"Keio J Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"Mantovani A.","year":"2022","unstructured":"Mantovani A.; Petracca G.; Beatrice G.; Csermely A.; Lonardo A.; Schattenberg J.M.; Tilg H.; Byrne C.D.; Targher G.; Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis. Gut  2022,71,156-162","journal-title":"Gut"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","volume":"71","author":"Mantovani A.","year":"2022","unstructured":"Mantovani A.; Petracca G.; Beatrice G.; Csermely A.; Tilg H.; Byrne C.D.; Targher G.; Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies. Gut  2022,71,778-788","journal-title":"Gut"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.102063","volume":"47","author":"Zhang P.","year":"2023","unstructured":"Zhang P.; Dong X.; Zhang W.; Wang S.; Chen C.; Tang J.; You Y.; Hu S.; Zhang S.; Wang C.; Wen W.; Zhou M.; Tan T.; Qi G.; Li L.; Wang M.; Metabolic-associated fatty liver disease and the risk of cardiovascular disease. Clin Res Hepatol Gastroenterol  2023,47","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11655-012-0993-2","volume":"18","author":"Dong H.","year":"2012","unstructured":"Dong H.; Lu F.E.; Zhao L.; Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin J Integr Med  2012,18,152-160","journal-title":"Chin J Integr Med"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.967623","volume":"13","author":"Lei S.","year":"2022","unstructured":"Lei S.; Zhao S.; Huang X.; Feng Y.; Li Z.; Chen L.; Huang P.; Guan H.; Zhang H.; Wu Q.; Chen B.; Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: A network pharmacology study and in vivo experimental validation. Front Pharmacol  2022,13","journal-title":"Front Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"19288","DOI":"10.1038\/srep19288","volume":"6","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Gu M.; Cai W.; Yu L.; Feng L.; Zhang L.; Zang Q.; Wang Y.; Wang D.; Chen H.; Tong Q.; Ji G.; Huang C.; Dietary component isorhamnetin is a PPAR\u03b3 antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. Sci Rep  2016,6,19288","journal-title":"Sci Rep"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"16210","DOI":"10.1038\/s41598-019-52736-y","volume":"9","author":"Ganbold M.","year":"2019","unstructured":"Ganbold M.; Owada Y.; Ozawa Y.; Shimamoto Y.; Ferdousi F.; Tominaga K.; Zheng Y.W.; Ohkohchi N.; Isoda H.; Isorhamnetin alleviates steatosis and fibrosis in mice with nonalcoholic steatohepatitis. Sci Rep  2019,9,16210","journal-title":"Sci Rep"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.876550","volume":"13","author":"Jiang J.J.","year":"2022","unstructured":"Jiang J.J.; Zhang G.F.; Zheng J.Y.; Sun J.H.; Ding S.B.; Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity. Front Pharmacol  2022,13","journal-title":"Front Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1515\/jbcpp-2020-0423","volume":"32","author":"Saleh Al-Maamari J.N.","year":"2021","unstructured":"Saleh Al-Maamari J.N.; Rahmadi M.; Panggono S.M.; Prameswari D.A.; Pratiwi E.D.; Ardianto C.; Balan S.S.; Suprapti B.; The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. J Basic Clin Physiol Pharmacol  2021,32,637-644","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2021.110240","volume":"143","author":"Mu H.N.","year":"2021","unstructured":"Mu H.N.; Zhou Q.; Yang R.Y.; Tang W.Q.; Li H.X.; Wang S.M.; Li J.; Chen W.X.; Dong J.; Caffeic acid prevents non-alcoholic fatty liver disease induced by a high-fat diet through gut microbiota modulation in mice. Food Res Int  2021,143","journal-title":"Food Res Int"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1177\/09603271221146780","volume":"42","author":"Zhao L.","year":"2023","unstructured":"Zhao L.; Yang L.; Ahmad K.; Kaempferol ameliorates palmitate-induced lipid accumulation in HepG2 cells through activation of the Nrf2 signaling pathway. Hum Exp Toxicol  2023,42","journal-title":"Hum Exp Toxicol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/fsn3.1339","volume":"8","author":"Rakib A.","year":"2020","unstructured":"Rakib A.; Ahmed S.; Islam M.A.; Haye A.; Uddin S.M.N.; Uddin M.M.N.; Hossain M.K.; Paul A.; Emran T.B.; Antipyretic and hepatoprotective potential of Tinospora crispa and investigation of possible lead compounds through in silico approaches. Food Sci Nutr  2020,8,547-556","journal-title":"Food Sci Nutr"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1002\/fsn3.2548","volume":"9","author":"Che D.N.","year":"2021","unstructured":"Che D.N.; Shin J.Y.; Kang H.J.; Cho B.O.; Park J.H.; Wang F.; Hao S.; Sim J.S.; Sim D.J.; Jang S.I.; Ameliorative effects of Cirsium japonicum extract and main component cirsimaritin in mice model of high-fat diet-induced metabolic dysfunction-associated fatty liver disease. Food Sci Nutr  2021,9,6060-6068","journal-title":"Food Sci Nutr"},{"key":"ref=53","first-page":"284","volume":"11","author":"Ivan L.","year":"2023","unstructured":"Ivan L.; Uyy E.; Suica V.I.; Boteanu R.M.; Cerveanu-Hogas A.; Hansen R.; Antohe F.; Hepatic alarmins and mitochondrial dysfunction under residual hyperlipidemic stress lead to irreversible NAFLD. J Clin Transl Hepatol  2023,11,284-294","journal-title":"J Clin Transl Hepatol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"939","DOI":"10.14218\/JCTH.2022.00067","volume":"10","author":"Clare K.","year":"2022","unstructured":"Clare K.; Dillon J.F.; Brennan P.N.; Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. J Clin Transl Hepatol  2022,10,939-946","journal-title":"J Clin Transl Hepatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4314\/ajtcam.v11i1.34","volume":"11","author":"Yang Q.","year":"2014","unstructured":"Yang Q.; Xu Y.; Feng G.; Hu C.; Zhang Y.; Cheng S.; Wang Y.; Gong X.; p38 MAPK signal pathway involved in anti-inflammatory effect of Chaihu-Shugan-San and Shen-ling-bai-zhu-San on hepatocyte in non-alcoholic steatohepatitis rats. AJTCAM  2014,11,213-221","journal-title":"AJTCAM"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms21176006","volume":"2020","author":"Zhang Z.","year":"2020","unstructured":"Zhang Z.; Li M.; Zhang X.; Zheng N.; Zhao S.; Wang J.; A novel urease inhibitor of ruminal microbiota screened through molecular docking. Int J Mol Sci  2020,2020,21","journal-title":"Int J Mol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"18169","DOI":"10.1002\/jcp.28450","volume":"234","author":"Shen X.","year":"2019","unstructured":"Shen X.; Guo H.; Xu J.; Wang J.; Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol  2019,234,18169-18179","journal-title":"J Cell Physiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bcp.2019.07.008","volume":"168","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Fan D.; Ginsenoside Rg5 induces G2\/M phase arrest, apoptosis and autophagy via regulating ROS-mediated MAPK pathways against human gastric cancer. Biochem Pharmacol  2019,168,285-304","journal-title":"Biochem Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijms20143415","volume":"2019","author":"Wang K.","year":"2019","unstructured":"Wang K.; Chen B.; Yin T.; Zhan Y.; Lu Y.; Zhang Y.; Chen J.; Wu W.; Zhou S.; Mao W.; Tan Y.; Du B.; Liu X.; Ho H.I.; Xiao J.; N-methylparoxetine blocked autophagic flux and induced apoptosis by activating ROS-MAPK pathway in non-small cell lung cancer cells. Int J Mol Sci  2019,2019,20","journal-title":"Int J Mol Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.mce.2017.10.010","volume":"470","author":"Liao X.","year":"2018","unstructured":"Liao X.; Song L.; Zhang L.; Wang H.; Tong Q.; Xu J.; Yang G.; Yang S.; Zheng H.; LAMP3 regulates hepatic lipid metabolism through activating PI3K\/Akt pathway. Mol Cell Endocrinol  2018,470,160-167","journal-title":"Mol Cell Endocrinol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.biopha.2018.06.089","volume":"106","author":"Fan Y.","year":"2018","unstructured":"Fan Y.; He Z.; Wang W.; Li J.; Hu A.; Li L.; Yan L.; Li Z.; Yin Q.;  Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS\/PI3K\/AKT signaling pathway. Biomed pharmacoth,  2018,106,733-737","journal-title":"Biomed pharmacoth,"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1080\/13880209.2022.2106250","volume":"60","author":"Xu Z.","year":"2022","unstructured":"Xu Z.; Wu F.W.; Niu X.; Lu X.P.; Li Y.R.; Zhang S.T.; Ou J.Z.; Wang X.M.; Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease. Pharm Biol  2022,60,1819-1838","journal-title":"Pharm Biol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/ene.15656","volume":"30","author":"Li W.","year":"2023","unstructured":"Li W.; Li R.; Yan S.; Zhao Z.; Shan Y.; Qi Z.; Lu J.; Effect of APOE \u03b54 genotype on amyloid-\u03b2, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment. Eur J Neurol  2023,30,587-596","journal-title":"Eur J Neurol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/liv.15509","volume":"43","author":"Pirola C.J.","year":"2023","unstructured":"Pirola C.J.; Sookoian S.; COVID-19 and non-alcoholic fatty liver disease: Biological insights from multi-omics data. Liver Int  2023,43(3),580-587","journal-title":"Liver Int"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00018-022-04629-z","volume":"80","author":"Lee S.M.","year":"2023","unstructured":"Lee S.M.; Muratalla J.; Karimi S.; Diaz-Ruiz A.; Frutos M.D.; Guzman G.; Ramos-Molina B.; Cordoba-Chacon J.; Hepatocyte PPAR\u03b3 contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice, Cellular and molecular life sciences. Cell Mol Life Sci  2023,80,39","journal-title":"Cell Mol Life Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1111\/liv.15441","volume":"42","author":"Ni X.X.","year":"2022","unstructured":"Ni X.X.; Ji P.X.; Chen Y.X.; Li X.Y.; Sheng L.; Lian M.; Guo C.J.; Hua J.; Regulation of the macrophage-hepatic stellate cell interaction by targeting macrophage peroxisome proliferator-activated receptor gamma to prevent non-alcoholic steatohepatitis progression in mice. Liver Int  2022,42(12),2696-2712","journal-title":"Liver Int"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118868","volume":"266","author":"Diniz T.A.","year":"2021","unstructured":"Diniz T.A.; de Lima E.A.; Junior; Teixeira, A.A.; Biondo, L.A.; da Rocha, L.A.F.; Valad\u00e3o, I.C.; Silveira, L.S.; Cabral-Santos, C.; de Souza, C.O.; Rosa Neto, J.C. Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-\u03b1 signaling in obese mice. Life Sci  2021,266","journal-title":"Life Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s12079-022-00678-y","volume":"16","author":"Abolfazli P.","year":"2022","unstructured":"Abolfazli P.; Aghajanzadeh T.; Ghaderinasrabad M.; Apue Nchama C.N.; Mokhlesi A.; Talkhabi M.; Bioinformatics analysis reveals molecular connections between non-alcoholic fatty liver disease (NAFLD) and COVID-19. J Cell Commun Signal  2022,16,609-619","journal-title":"J Cell Commun Signal"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7251450","volume":"2022","author":"Gao R.","year":"2022","unstructured":"Gao R.; Zhang X.; Zhou Z.; Sun J.; Tang X.; Li J.; Zhou X.; Shen T.; Pharmacological mechanism of ganlu powder in the treatment of NASH based on network pharmacology and molecular docking. Dis Markers  2022,2022","journal-title":"Dis Markers"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Duan Y.","year":"2022","unstructured":"Duan Y.; Pan X.; Luo J.; Xiao X.; Li J.; Bestman P.L.; Luo M.; Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol  2022,13","journal-title":"Front Immunol"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107265","volume":"9,","author":"Negrin K.A.","year":"2014","unstructured":"Negrin K.A.; Roth Flach R.J.; DiStefano M.T.; Matevossian A.; Friedline R.H.; Jung D.; Kim J.K.; Czech M.P.; IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One  2014,9,","journal-title":"PLoS One"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734099305489240702075128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/231875\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734099305489240702075128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T11:57:35Z","timestamp":1754999855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/231875\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115734099305489240702075128","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}